Candel Therapeutics, Inc. — Director's Dealing 2021

Aug 4, 2021

SEC Form 4/A — Form 4/A

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-29

Reporting Person: Manning Paul B (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-29	Common Stock	C	679158	—	Acquired	679158	Indirect
2021-07-29	Common Stock	C	553752	—	Acquired	553752	Indirect
2021-07-29	Common Stock	P	1625000	$8.00	Acquired	1681000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-29	Series B Preferred Stock	$	C	1669303	Disposed		Common Stock (679158)	Indirect
2021-07-29	Series B Preferred Stock	$	C	1361069	Disposed		Common Stock (553752)	Indirect

Footnotes

F1: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F2: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F4: Includes shares held jointly with spouse.